Arrowhead and takeda announce topline results from sequoia phase 2 study of fazirsiran in patients with alpha-1 antitrypsin deficiency-associated liver disease

Osaka, japan & cambridge, mass. & pasadena, calif.--( business wire )--takeda (tse:4502/nyse:tak) and arrowhead pharmaceuticals inc. (nasdaq: arwr) today announced topline results from the phase 2 sequoia clinical study of investigational fazirsiran (tak-999/aro-aat) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (aatd-ld). the companies also provided an outline of a phase 3 study that was co-developed by takeda and arrowhead and will be conducted by takeda. additional sequoia study results are planned to be presented at a future medical meeting and submitted for publication. arrowhead will host a webcast call for investors today, january 9, 2023, at 8:30 a.m. et to review the phase 2 data. to register for the webcast, visit the events and presentations page under the investors section of www.arrowheadpharma.com.
TAK Ratings Summary
TAK Quant Ranking